Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-10-11 4:02 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Octagon Capital Advisors LP | 8,559,000 9.1% | 8,559,000 (New Position) | View |
| 2024-07-18 4:10 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | GREAT POINT PARTNERS LLC | 8,559,000 9.99% | 8,559,000 (New Position) | View |
| 2024-02-14 6:41 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | RA CAPITAL MANAGEMENT L.P. | 3,472,106 9.99% | 1,417 (+0.04%) | View |
| 2024-02-14 4:51 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Nantahala Capital Management LLC | 3,475,713 9.9% | 2,268,297 (+187.86%) | View |
| 2024-02-14 3:18 pm Unchanged | 13G | Unicycive Therapeutics Inc. UNCY | ARMISTICE CAPITAL LLC | 976,000 2.73% | 0 (Unchanged) | View |
| 2024-02-02 8:32 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Nantahala Capital Partners Limited Partnership | 2,121,753 6.1% | 2,121,753 (New Position) | View |
| 2024-01-22 4:27 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Logos Global Management LP | 3,469,927 9.9% | 3,469,927 (New Position) | View |
| 2023-07-14 4:30 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Vivo Opportunity Fund Holdings L.P. | 59,961,729 9.99% | 59,961,729 (New Position) | View |
| 2023-07-06 5:23 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | BIOTECHNOLOGY VALUE FUND L P | 3,470,225 9.99% | 3,470,225 (New Position) | View |
| 2023-07-06 4:30 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | RA CAPITAL MANAGEMENT L.P. | 3,470,689 9.99% | 3,470,689 (New Position) | View |
| 2023-02-14 4:52 pm Sale | 13G | Unicycive Therapeutics Inc. UNCY | Nantahala Capital Management LLC | 1,207,416 8% | -39,340 (-3.16%) | View |
| 2023-02-14 1:41 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | ARMISTICE CAPITAL LLC | 976,000 6.08% | 176,000 (+22.00%) | View |
| 2022-02-14 9:37 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | ARMISTICE CAPITAL LLC | 800,000 5.1% | 800,000 (New Position) | View |
| 2022-02-14 08:35 am Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Nantahala Capital Management LLC | 1,246,756 8% | 1,246,756 (New Position) | View |
| 2022-02-14 06:11 am Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Altium Capital Management LP | 176,000 1.2% | 176,000 (New Position) | View |
| 2022-01-20 4:23 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Rosalind Advisors Inc. | 969,484 6.5% | 156,929 (+19.31%) | View |
| 2021-09-23 4:54 pm Purchase | 13G | Unicycive Therapeutics Inc. UNCY | Rosalind Advisors Inc. | 812,555 5.6% | 812,555 (New Position) | View |